Allstate Corporation (The)
A large-scale personal-lines insurer regaining underwriting discipline
Allstate has tightened underwriting, pushed through rate actions, and simplified its portfolio with divestitures, producing a sharp profitability recovery since late 2024. The second quarter of 2025 showed a 91.1 recorded combined ratio, $1.28 billion of property-liability underwriting income, and adjusted EPS of 5.94, with trailing twelve‑month adjusted ROE of 28.6. Net investment income also strengthened as the fixed income book reset to higher yields.
Despite this rebound, the core economics remain those of a competitive, regulated industry exposed to catastrophe volatility. First quarter 2025 illustrated the cyclicality with $2.20 billion of catastrophe losses partly offset by $1.1 billion of reinsurance recoveries.
Allstate continued to streamline by closing the $2.0 billion sale of Employer Voluntary Benefits on April 1 and the Group Health sale on July 1, taking total proceeds for these health businesses to $3.25 billion, while a separate $1.25 billion stop‑loss transaction with Nationwide was announced for the second half of 2025.
Allstate (The) a-t-elle un rempart concurrentiel (moat) solide ?
Allstate’s moat is narrow and based on brand, scale, proprietary data, and multi‑channel distribution (exclusive agents, independent agents from National General, and direct). Claims infrastructure and telematics data (Arity, Drivewise) aid pricing and retention.
However, switching costs for personal auto are modest, price shopping is common, and Progressive’s structural expense advantage limits cost‑based moats. Regulatory approval gates pricing and can delay reactions to loss trends, while catastrophe exposure challenges durability.
Total policies in force reached 208 million, signaling scale but not true network effects. Overall, the moat is real yet less durable than payment networks or software toll roads.
Allstate (The) a-t-elle un pricing power dans son secteur ?
Regulation caps pure pricing autonomy, but Allstate has demonstrated the ability to earn higher average premiums across lines post‑2022 inflation. Auto rate increases moderated to a 0.4 percent annualized premium impact in Q2 2025 as loss trends cooled, and policies in force started growing again.
Homeowners average gross written premium rose double‑digits year over year. This shows recoverable pricing power, albeit state‑by‑state and cyclical.
Quelle est la prévisibilité de l'activité de Allstate (The) ?
Underlying results are improving, but catastrophes and regulation drive volatility. Q1 2025 saw $2.20 billion of catastrophe losses, partially offset by $1.1 billion of reinsurance recoveries, before strong Q2 underwriting. Underlying combined ratio for H1 2025 was 81.3 vs 86.1 a year ago, but reported ratios swing with weather.
The business is not as predictable as toll‑like payment networks or software subscriptions.
Allstate (The) est-elle financièrement solide ?
Balance sheet is solid for a P&C insurer. As of June 30, 2025, investments were $77.4 billion, debt was $8.09 billion, and Allstate shareholders’ equity was $24.0 billion. Book value per share was $82.40 and TTM adjusted ROE was 28.6 percent, reflecting restored earnings power.
The catastrophe reinsurance program meaningfully cushioned Q1 losses. Leverage and liquidity appear appropriate for the risk profile.
Quelle est l'efficacité de la stratégie d'allocation de capital de Allstate (The) ?
Management exited non‑core health benefits businesses (Employer Voluntary Benefits closed April 1 with a $643 million after‑tax gain; Group Health closed July 1) and announced a separate stop‑loss sale to Nationwide for $1.25 billion. Capital returned to shareholders included a dividend hike to 1.00 and $341 million of Q2 repurchases.
The National General acquisition broadened distribution earlier in the strategy. Track record is improving, though underwriting execution remains the primary value driver.
Allstate (The) a-t-elle une direction de haute qualité ?
CEO Tom Wilson and team have navigated a difficult 2022‑2023 period with decisive rate actions, mix shifts, reinsurance, and portfolio simplification. Communication and disclosure quality are high via quarterly supplements and detailed segment metrics.
Execution delivered an auto recorded combined ratio of 86.0 in Q2 and materially higher investment income, supporting confidence in current leadership, while recognizing the industry’s uncontrollable catastrophe element.
Allstate (The) est-elle une entreprise de qualité ?
Allstate Corporation (The) est une entreprise de qualité an average avec un score de qualité de 62/100
Predicted probability of operating margin improvement over the next 12 months
- Underwriting profitability is back: Q2 2025 recorded combined ratio 91.1 and underlying 79.5, with auto at an 86.0 recorded combined ratio.
- Capital deployment improved: dividend raised 9 percent to 1.00 per share and $341 million of buybacks executed in Q2, backed by $77.4 billion of investments.
- Portfolio simplification: exited Employer Voluntary Benefits and Group Health for a combined $3.25 billion of proceeds; separate $1.25 billion stop‑loss sale to Nationwide announced.
- TTM owner‑earnings proxy: summing adjusted EPS Q3‑2024 through Q2‑2025 gives about 21.05 per share (3.91 + 7.67 + 3.53 + 5.94).
- Structural headwinds persist: catastrophe exposure and regulated pricing temper moat durability and predictability.
Quelle est le prix juste de l'action Allstate (The) ?
Allstate (The) est-elle un bon investissement à $216 ?
L'analyse suivante est fournie à des fins d'information et d'éducation uniquement. Elle ne constitue pas un conseil financier, un conseil en investissement ou une recommandation d'achat ou de vente de titres. Les opinions exprimées sont basées sur des informations publiques et des données historiques. Beanvest et ses contributeurs peuvent détenir des positions dans les titres mentionnés. Les investisseurs doivent effectuer leur propre diligence raisonnable ou consulter un conseiller financier agréé avant de prendre toute décision d'investissement.